Valuation: BLS Pharmaceuticals Limited

Market Cap 213M 149M 131M 122M 112M 210M 14.35B 1.45B 565M 7.05B 559M 547M 24.39B P/E 2024
-0.72x
P/E 2025 17.8x
Enterprise Value 207M 145M 127M 118M 108M 204M 13.94B 1.4B 548M 6.85B 543M 532M 23.69B EV / Sales 2024
1.03x
EV / Sales 2025 2.82x
Free-Float
45.12%
Yield 2024 *
-
Yield 2025 -
1 day-0.59%
1 week-2.89%
Current month-9.68%
1 month-11.58%
3 months+27.27%
6 months+110.00%
Current year+100.00%
1 week 0.82
Extreme 0.825
0.9
1 month 0.76
Extreme 0.76
0.97
Current year 0.36
Extreme 0.36
1.1
1 year 0.33
Extreme 0.33
1.1
3 years 0.04
Extreme 0.04
1.1
5 years 0.04
Extreme 0.04
1.1
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 2023-05-18
Director of Finance/CFO 72 2016-08-31
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 2012-12-04
Director/Board Member 72 2022-06-29
Director/Board Member - 2023-05-18
Date Insider Type Main position Quantity % Market Cap.
5/14/26 Buy 5,000,000 0.2202%
5/14/26 Fiscal year 5,000,000 0.2202%
3/22/26 Buy

Chief Executive Officer

1,800,000 0.0804%
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%-2.89%+68.00%+342.11% 135M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average +0.14%+0.46%+56.06%+132.62% 24.54B
Weighted average by Cap. +0.48%+0.91%+74.41%+136.40%

Financials

2024 2025
Net sales 9.64M 6.74M 5.92M 5.51M 5.05M 9.5M 649M 65.4M 25.55M 319M 25.31M 24.77M 1.1B 29.28M 20.48M 17.98M 16.72M 15.35M 28.84M 1.97B 199M 77.59M 969M 76.87M 75.21M 3.35B
Net income -13.33M -9.32M -8.18M -7.61M -6.98M -13.12M -897M -90.38M -35.31M -441M -34.98M -34.23M -1.53B 4.9M 3.43M 3.01M 2.8M 2.57M 4.83M 330M 33.24M 12.99M 162M 12.87M 12.59M 561M
Net Debt -318K -222K -195K -181K -166K -313K -21.39M -2.15M -842K -10.51M -834K -816K -36.35M -6.13M -4.29M -3.77M -3.5M -3.22M -6.04M -413M -41.61M -16.25M -203M -16.1M -15.76M -702M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
26-07-24 A$0.8400 -0.59% 98,518
26-07-23 A$0.8450 -1.17% 84,378
26-07-22 A$0.8550 +1.79% 151,936
26-07-21 A$0.8400 -5.62% 77,191
26-07-20 A$0.8900 +2.89% 69,727

Annual profits - Rate of surprise